Dr. John L. Goudreau

powered by
COS Expertise®
Michigan State University
College of Osteopathic Medicine
Neurology
Associate ProfessorAppointed: 2006
Michigan State University
College of Osteopathic Medicine
Pharmacology & Toxicology
Associate ProfessorAppointed: 2006
Michigan State University
Neurology
Translational Neurobiology Research UnitAppointed: 2005
Professional Headshot of John L. Goudreau

Mailing Address

Department of Neurology
A217 Clinical Center
Michigan State University
East Lansing, Michigan 48824
United States

Contact Information

Phone: (517) 432-9277
Fax: (517) 432-3713
Mobile: (517) 202-4871
Pager: (517) 232-2847
john.goudreau@ht.msu.edu

Qualifications

Board Certified in Neurology, American Osteopathic Board of Neurology and Psychiatry, 2004.
Board Certified in Neurology, American Board of Medical Specialties, American Board of Neurology and Psychiatry, 2002.
Fellowship, Mayo Foundation for Medical Education and Research, Movement Disorders, 2001.
Residency, Mayo Foundation for Medical Education and Research, Neurology, 2000.
D.O., Michigan State University, 1995.
Ph.D., Michigan State University, Pharmacology-Neuroscience, 1994.
B.A., Michigan State University, Chemistry, 1988.
B.S., Michigan State University, Medical Technology, 1988.

Expertise and Research Interests

Neurotoxicology
Animal models of Parkinson's disease
In vitro models of Parkinson's disease
SNP and RFLP polymorphism genotyping
High perfromance liquid chromatography
Immunohistochemistry
Stereological cell counting
Primary neuronal cultures
Western blot
Northern blot
Single cell microdissection and gene expression analsysis
Confocal microscopy
Motor behavior analysis

Future Research

1. Neuroprotective effects of target compounds in chronic animal models of Parkinson's disease
2. Role of alpha-synuclein if response to environmental neurotoxicants
3. Selective resistance of hypothalamic dopamine neurons to neurodegeneration
4. Clinical trials of symptomatic and neuroprotective agents in Parkinson's disease

Industrial Relevance

Extensive experience in conducting clinical research for pharmaceutical industry-related and NIH-sponsored Phase II and III trials.

Keywords

COS Keywords:

Animal Models, Confocal Microscopy, Dopamine, Gene Expression, Genetics, Immunohistochemistry, Liquid Chromatography, Neurology, Parkinson's Disease, Pharmacology, Toxicology.

Additional Terms:

Animal Models, Dopamine, Genetics, Movement Disorders, Neuroprotection, Parkinson.

Memberships

American Academy of Neurology
American Osteopathic Association
American Society for Clinical Pharmacology and Therapeutics
Movement Disorders Society
Parkinson Study Group
Society for Neuroscience

Honors and Awards

2000, Mayo Brothers Distinguished Fellowship Award, Mayo Foundation, Mayo Clinic
1994, Lawrence D. Sills Research Award, College of Osteopathic Medicine, Michigan State University
1992, Student Research Travel Award, American Society for Pharmacology and Experimental Therapeutics, Michigan State University
1988-1995, Medical Scientist Training Program Honors Fellowship, College of Osteopathic Medicine, Michigan State University
1988, Academic Excellence Award, College of Natural Science, Michigan State University

Previous Positions

2001, Assistant Professor, Michigan State University, Neurology
2001, Assistant Professor, Michigan State University, Pharmacology & Toxicology
1999-2000, Instructor, Mayo Foundation for Medical Education and Research, Mayo Medical School, Neurology
1997-2000, Resident, Mayo Foundation for Medical Education and Research, Neurology
1996-1997, Intern, Scottsdale
1995-1996, Intern, Botsford General Hospital

Funding Received

  • USAMRAA: [ERMS 06144019] Environmental neurotoxin exposure-induced nuclear-mitochondrial cascade mechanisms of neurodegeneration, 2007 to 2011.
  • Boehringer Ingelheim: [BI 246.622] A randomized, double-blind, active and placebo controlled, efficacy study of pramipexole dosing strategies over a 12-week treatment phase in early Parkinson's disease patients (PramiBID), 2007 to 2008.
  • Solvay Pharmaceuticals: [S308.3.002] The Mondrian study:A multicenter, randomized, double-blind, placebo-controlled, parallel group study of SLV308 as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations, 2007 to 2009.
  • Solvay Pharmaceuticals: [S308.3.007] An extension of the Mondrian study: An open label SLV308 safety extension to study S308.3.002 in patients with Parkinson's disease experiencing motor fluctuations, 2007 to 2009.
  • National Institutes of Health (NIH): [U10 NS053380-01] Michigan State University Parkinson Disease Clinical Center, 2006 to 2011.
  • Teva Pharmaceuticals: [TVP 1012/500] Phase IIIb Trial of Rasagiline as a Neuroprotective Therapy in Parkinson's Disease, 2006 to 2009.
  • National Institutes of Health (NIH): [R21 NS049057-01A1] Neuroprotective factors in hypothalamic dopamine neurons, 2005 to 2007.
  • National Institutes of Health (NIH): [R21 NS051406-01] Apocynin neuroprotection in a Parkinson disease model, 2005 to 2007.
  • Viagra Research Grant Program (Pfizer): Neuroprotective Effects of Sildenafil Citrate in an Animal Model of Parkinson's Disease [1037], $50,000, 2004 to .
  • Pfizer: [66E-CNS-0618-001] A phase II-randomized, double blind, placebo-controlled, dose-response study of the efficacy and safety of sumanirole in patients with idiopathic restless legs syndrome, 2003 to 2004.
  • Pfizer: [66E-CNS-0618-007] A long-term, open-label, flexible-dose study of the efficacy and safety of sumanirole in patients with idiopathic restless legs syndrome, 2003 to .
  • Fellowship Program in Academic Medicine, National Medical Fellowships, Inc.: Hypothalamic dopamine neurons versus nigrostriatal dopamine neurons: selective degeneration in an in vitro model of Parkinson's disease, 2003 to 2003.
  • Michigan State University Foundation: Neuroprotective effects of alpha synuclein using an in vitro model of Parkinson's disease, $50,000, 2002 to 2004.
  • Raymond Bauer Student Fellowship, Michigan Parkinson Foundation: The Role of a-Synuclein and Environmental Toxins in Parkinson's Disease, 2002 to 2003.

Publications

  • Behrouz, B, Drolet, RE, Sayed, Z, Lookingland, KJ, Goudreau, JL (2007) Unique Responses to Mitochondrial Complex I Inhibition in Tuberoinfundibular Dopamine Neurons May Impart Resistance to Toxic Insult, Neuroscience, 147, 592-598
  • Duka, T, Ruznak, M, Drolet, RE, Duka, V, Wersinger, C, Goudreau, JL, Sidhu, A (2006) Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism, FASEB Journal, 20, 2302-2312
  • Goudreau, JL (2006) Medical management of advanced Parkinson's disease., Clin Geriatr Med, 22, 753-772
  • Drolet, RE, Behrouz, B, Lookingland, KJ, Goudreau, JL (2006) Substrate-mediated enhancement of phosphorylated tyrosine hydroxylase in nigrostriatal dopamine neurons: evidence for a role of alpha-synuclein, J Neurochemistry, 96, 950-959
  • Goudreau, JL (2006) Hereditary Spinocerebellar Degeneration, Neurological Therapeutics: Principles and Practice, 2nd Edition, London, Martin Dunitz, 2496-2509 pages (bookchapter)
  • Zheng, JL, Tang, LL, Zheng, SS, Zhan, RY, Zhou, YO, Goudreau, JL, Kaufman, D, Chen, A (2005) Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease., Mol Brain Res, 134, 155-161
  • Goudreau, JL, Ahlskog, JE (2005) Symptomatic Treatment of Parkinson's Disease: Levodopa, Parkinson's Disease, New York, CRC Press (bookchapter)
  • Drolet RE, Behrouz B, Lookingland KJ, Goudreau JL, Mice Lacking Alpha-Synuclein have an Attenuated Loss of Striatal Dopamine Following Prolonged Chronic MPTP Administration, Neurotoxicology, 25(5), September 2004
  • Albin RL, Frey KA, Goudreau JL, Sakurai SY, Practice parameter: initiation of treatment for ParkinsonĀ’s disease: an evidence-based review [Post-publication peer review], Neurology, December 2002
  • Van Gerpen JA, Goudreau JL, Dodick DW, Gertz MA, Amyloidosis presenting with intractable epistaxis and multiple cranial neuropathies, Neurology, 55(11), 1755-6, December 2000 Abstract
  • Goudreau JL, Wijdicks EF, Emery SF, Complications during apnea testing in the determination of brain death: predisposing factors, Neurology, 55(7), 1045-8, October 2000 Abstract
  • Lincoln S, Gwinn-Hardy K, Goudreau J, Chartier-Harlin MC, Baker M, Mouroux V, Richard F, Destee A, Becquet E, Amouyel P, Lynch T, Hardy J, Farrer M, No pathogenic mutations in the persyn gene in Parkinson's disease, Neuroscience Letters, 259(1), 65-6, 1999 Abstract
  • Goudreau JL, Falls WM, Lookingland KJ, Moore KE, Periventricular-hypophysial dopaminergic neurons innervate the intermediate but not the neural lobe of the rat pituitary gland, Neuroendocrinology, 62(2), 147-54, August 1995 Abstract
  • Goudreau JL, Wagner EJ, Lookingland KJ, Moore KE, gamma-Aminobutyric acid receptor-mediated regulation of periventricular-hypophysial dopaminergic neurons: possible role in mediating stress- and 5-hydroxytryptamine-induced decreases in neuronal activ, Journal of Pharmacology and Experimental Therapeutics, 271(2), 1000-6, November 1994 Abstract
  • Wagner EJ, Goudreau JL, Moore KE, Lookingland KJ, GABAergic regulation of tuberoinfundibular dopaminergic neurons in the male rat, Brain Research, 659(1-2), 194-200, 1994 Abstract
  • Goudreau JL, Lookingland KJ, Moore KE, 5-Hydroxytryptamine2 receptor-mediated regulation of periventricular-hypophysial dopaminergic neuronal activity and the secretion of alpha-melanocyte-stimulating hormone, Journal of Pharmacology and Experimental Therapeutics, 268(1), 175-9, January 1994 Abstract
  • Tian Y, Eaton MJ, Goudreau JL, Lookingland KJ, Moore KE, Neurochemical evidence that 5-hydroxytryptaminergic neurons tonically inhibit noradrenergic neurons terminating in the hypothalamus, Brain Research, 607(1-2), 215-21, 1993 Abstract
  • Goudreau JL, Manzanares J, Lookingland KJ, Moore KE, 5HT2 receptors mediate the effects of stress on the activity of periventricular hypophysial dopaminergic neurons and the secretion of alpha-melanocyte-stimulating hormone, Journal of Pharmacology and Experimental Therapeutics, 265(1), 303-7, April 1993 Abstract
  • Goudreau JL, Lindley SE, Lookingland KJ, Moore KE, Evidence that hypothalamic periventricular dopamine neurons innervate the intermediate lobe of the rat pituitary, Neuroendocrinology, 56(1), 100-5, July 1992 Abstract
  • Shukla R, Goudreau J, Mackenzie-Taylor D, Rech RH, Disruption of FR-40 by 5-HT agonists. II. Effects of chronic phenelzine or isocarboxazid, Pharmacology, Biochemistry and Behavior, 34(2), 283-7, October 1989 Abstract

Profile Details

Last Updated: 9/10/2007

COS Expertise ID #351887
Reference this profile directly: http://myprofile.cos.com/jlgoudreau